Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanh Lam

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Endocrinology|January 1, 2004
A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasisQiu Guo, Soumya P Sahoo, Pei-Ran Wang, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Endocrinology|January 1, 2004
A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasisQiu Guo, Soumya P Sahoo, Pei-Ran Wang, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Pageof 3